Rosuvastatin and atorvastatin in patients with acute coronary syndromes: head-to-head comparison of lipid-lowering and anti-inflammatory effects

Background. Hypercholesterolemia and inflammation both contribute to the pathogenesis of atherosclerosis its clinical manifestations. Statins, possessing lipid-lowering anti-inflammatory properties, are currently recommended in all ischemic syndromes. Purpose. To compare effects atorvastatin rosuvastatin on lipid inflammatory markers patients with acute coronary syndromes (ACS). Methods. Two hundred thirty-nine consecutive ACS, without familial hypercholesterolaemia no statin treatment preceding 4 weeks, were randomly assigned within 24 hours after hospital admission either 80 mg (119 patients) or 20 (120 patients). Lipid assessed before randomization 12 weeks treatment. Results. Both statins similarly reduced total cholesterol LDL-cholesterol at substantial stability weeks. At decreased from 129 mg/dL 71 group 126 group. Apolipoprotein B significantly groups. Otherwise, apolipoprotein A1 increased only. As a consequence, ApoB/ApoA1 ratio more No significant differences seen triglycerides, HDL-cholesterol Lipoprotein (a) levels. Among markers, hs-CRP, interleukin-6, interleukin 1-RA, TGF-β1, MMP-9 Interleukin-10 levels only randomized atorvastatin. Conclusions. A moderate dose provided similar effects, as compared high atorvastatin, large series markers. Rosuvastatin was effective than reducing ApoB/ApoA1. Considering these findings, daily may be an alternative